Treatment of Cervical Spinal Cord Injury with Imatinib – a safety and feasibility study

Karolinska University Hospital0 个研究点开始时间: 2014年12月15日最近更新: 2015年2月16日

适应症

试验速览

暂无简介。

•1.Men and women aged 18-80 years
•2.Clinical signs of cervical spinal cord injury due to trauma
•3.In otherwise good health condition as determined by past medical history, physical examination, laboratory tests and vital signs
•4.Patient that is conscious and oriented x 4 (regarding date/time, localisation, situation and personal details), with higher level of consciousness, i.e. Glasgow Coma Scale > 14, and is assessed to be competent to give informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 9
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1

•1.Diabetes (type I and II)
•2.Ongoing cancer treatment
•3.Known allergy to study drug Imatinib or its excipients
•4.On current therapy with drugs which may interfere with Imatinib, e.g. paracetamol, ketokonazol, itrakonazol, erythromycin and claritomycin Dexametason, phenytoin, karbamazepin, rifampizin, phenobarbital, fosphenytoin, primidon, Hypericum performatum (Johannesört).
•5.Female subjects lactating or with positive pregnancy test
•6.Known liver or kidney disease
•7.Any relevant surgical or medical condition which in the opinion of the investigator may interfere with the conduct of the study or the scientific results. This includes hemorrhagic conditions.

发起方

Karolinska University Hospital